CACMID/AMMI 2022 **P29**



G ZHANEL¹, J Kosar², M Baxter¹, R Dhami³, S Borgia⁴, N Irfan⁵, KS MacDonald¹, G Dow⁶, P Lagacé-Wiens¹, M Dubé⁷, M Bergevin⁸, Y Keynan¹, A Lee⁹, Z Chagla¹⁰, G Girouard¹¹, A Walkty¹, J Karlowsky¹

¹University of Manitoba, Winnipeg, MB; ²Royal University Hospital, Saskatoon, SK; ³London Health Sciences Centre, London, ON; ⁴William Osler Health System, Brampton, ON; ⁵Hamilton Health Sciences Centre, Hamilton, ON; ⁶The Moncton Hospital, NB; ⁷Sainte-Croix Hospital, Drummondville, QC; ⁸Cité de la Santé, Montreal, QC; ⁹Scarborough Health Network, Toronto, ON, ¹⁰St. Joseph's Healthcare, Hamilton, ON; ¹¹Dr. Georges L. Dumont University Hospital, Moncton, NB.

Introduction

Over the past several years in Canada, when new IV antimicrobials are approved and introduced onto the market, they are used primarily by infectious diseases/medical microbiology specialists and frequently used to treat "off-label" infectious indications. There is commonly limited data sharing between clinicians regarding why they chose to use these new IV antimicrobials (i.e., because of failure, resistance, or adverse effects associated with use of other antimicrobial agents), the types of infections treated, and how (i.e., dosage regimen, duration of therapy, as monotherapy or in combination with one or more other antimicrobial agents) they use new IV antimicrobial agents in real world scenarios. The CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) is an initiative coordinated by the Canadian registry Antimicrobial Resistance Alliance (CARA). CLEAR is a national usage registry platform that enables the accumulation of knowledge regarding the clinical usage of new IV recently introduced into the Canadian antimicrobials In this study, CLEAR is accumulating data on marketplace. ceftobiprole across IV Canada usage of the (https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=A8EHM8JJRF). CLEAR also has IV ceftolozane/tazobactam and IV fosfomycin


in the registry. Links to access these surveys: https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=F7JXNDFXEF https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=WHWT7RDK7X


Materials and Methods


An IV ceftobiprole usage questionnaire was developed using the input of infectious disease/medical microbiology specialists (physicians and pharmacists) across Canada. The CLEAR registry protocol/questionnaire was submitted to and received approval by the Human Ethics Committee at the University of Manitoba (Winnipeg, Canada; April 2019).


Using the web-based research data management program, REDCapTM (Research Electronic Data Capture), clinicians (physicians and clinical pharmacists) responded directly to the usage questionnaire online starting June 2019. The REDCap™ online link survey (https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=A8EHM8JJRF)

was distributed via email to >330 CLEAR participants (members of the Association of Medical Microbiology and Infectious Diseases Canada [AMMI] and Canadian Society of Hospital Pharmacists [CSHP]). Clinicians were sent an email every 2 months encouraging their participation in CLEAR. A series of drop-down menus and short answer questions allowed for rapid (~3 minutes) completion of the survey. Clinicians were encouraged to voluntarily complete usage questionnaires for as many patients as possible. The CLEAR ceftobiprole questionnaires received by March 1, 2022 were tabulated and results presented are based on 65 patient treatment surveys.












Real-life Experience with Ceftobiprole in Canada: Results from the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry


Results


Below are the cumulative tabulated results of the questions asked in the CLEAR ceftobiprole usage survey questionnaires as of March 1, 2022. The following tables are based on a total of 65 patient treatment surveys.














# (%) of Patients	Ceftobiprole Dose
2 (3.1%)	1 Gram Q8H
1 (1.5%)	1 Gram Q12H
43 (66.2%)	500mg Q8H
8 (12.3%)	500mg Q12H
10 (15.4%)	250mg Q24H
1 (1.5%)	250mg Q12H
8 (12.3%) 10 (15.4%)	500mg Q12H 250mg Q24H 250mg Q12H









Dr. George G. Zhanel Department of Medical Microbiology Max Rady College of Medicine MS673-820 Sherbrook Street Winnipeg, MB R3A 1R9 Email: ggzhanel@pcsinternet.ca

Conclusions

With Another otic?	
UNKNOWN	
1.5%	

- 1. Ceftobiprole is used to treat a variety of infections including endocarditis, healthcare-acquired bacterial pneumonia, and bone and joint infections with the majority of patients having bacteremia
- 2. Ceftobiprole is almost exclusively used for the treatment of infections caused by MRSA
- 3. Ceftobiprole is primarily used due to failure of previously prescribed antibiotics
- 4. Ceftobiprole is frequently used without antimicrobial susceptibility testing
- 5. Ceftobiprole is frequently combined with a second MRSA agent such as daptomycin or vancomycin
- 6. The most common IV dosage administered was 500mg Q8H and the most administration was using prolonged (on label) infusion (≥ 2 hours)
- 7. Ceftobiprole is frequently used for durations >10 days
- 8. Ceftobiprole treatment is associated with high rates of microbiological and clinical efficacy
- 9. Ceftobiprole is associated with an excellent safety profile

Acknowledgements

The authors thank all the infectious diseases and medical microbiology specialists (physicians and pharmacists) across Canada for submitting patient data and for their support of CLEAR.

AVIR Pharma provided an unrestricted education grant.

Survey Access

CLEAR – ceftobiprole link https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=A8EHM8JJRF